Molecular Pharmacology Stock Current Liabilities
| MLPH Stock | USD 0.0001 0.00 0.00% |
Molecular Pharmacology fundamentals help investors to digest information that contributes to Molecular Pharmacology's financial success or failures. It also enables traders to predict the movement of Molecular Pink Sheet. The fundamental analysis module provides a way to measure Molecular Pharmacology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecular Pharmacology pink sheet.
Molecular |
Molecular Pharmacology Company Current Liabilities Analysis
Molecular Pharmacology's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Molecular Pharmacology Current Liabilities | 2.11 M |
Most of Molecular Pharmacology's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Pharmacology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Molecular Pharmacology has a Current Liabilities of 2.11 M. This is 99.88% lower than that of the Biotechnology sector and 99.61% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.97% higher than that of the company.
Molecular Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Pharmacology's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Molecular Pharmacology could also be used in its relative valuation, which is a method of valuing Molecular Pharmacology by comparing valuation metrics of similar companies.Molecular Pharmacology is currently under evaluation in current liabilities category among its peers.
Molecular Fundamentals
| Return On Asset | -5.69 | |||
| Current Valuation | 221.59 K | |||
| Shares Outstanding | 111.55 M | |||
| Price To Earning | (0.80) X | |||
| EBITDA | (98.11 K) | |||
| Net Income | (116.93 K) | |||
| Cash And Equivalents | 1.52 K | |||
| Total Debt | 175.33 K | |||
| Current Ratio | 0.28 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (105.41 K) | |||
| Beta | 42.97 | |||
| Market Capitalization | 26.77 K | |||
| Total Asset | 8.97 K | |||
| Working Capital | (2.1 M) | |||
| Current Asset | 9 K | |||
| Current Liabilities | 2.11 M | |||
| Net Asset | 8.97 K |
About Molecular Pharmacology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Pharmacology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Pharmacology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Pharmacology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.